Clinical Trial

Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

Study acronym: RAISE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
RAISE is an international, multicentre, single-arm phase II trial. The trial treatment consists of the addition of niraparib, 200 mg orally once daily to anti-PD-L1 antibody maintenance. The primary objective of this trial is to assess the clinical efficacy of the addition of niraparib to anti-PD-L1 monoclonal antibody maintenance treatment in patients with SLFN11-positive ED-SCLC which has not progressed following standard first-line chemo-immunotherapy.
Protocol Amendment History 22 amendments
This ClinicalTrials.gov record has been amended 22 times since 2023-01-30; most recent amendment 2026-05-27.
Status change: Not Yet Recruiting → Recruiting 2024-02-08
Trial Details
NCT Number NCT05718323
Lead Sponsor ETOP IBCSG Partners Foundation
Collaborators: GlaxoSmithKline, Development Limited
Conditions SCLC,Extensive Stage, SLFN11-positive
Enrollment 44 participants
Start Date 2023-12-20
Primary Completion 2026-12 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-29